As the first month of 2022 draws to a close, the internet is filled with trend forecasts for the coming year. Bloggers, Twitter influencers, and famous entrepreneurs have been, and continue to be, incredibly excited about the new possibilities presented by the explosion of Web3 innovation. But something you may have missed browsing NFT-backed celebrity pages or second-hand speculation is the launch of a new company called Altos Labs backed by former Amazon CEO Jeffrey Bezos.
The language that followed the launch was pretty much typical of a number of casual journalists talking about the longevity sector, and words like vague and secretive. I have written in previous articles that there are many misconceptions about the age sector, and this new round of headlines seems to confirm that this is still true.
Related Topics: The Future of Longevity Lies in Cryptovision
I think the longevity sector is about much more than secret deals with the richest people on the planet. The space is ripe for interested investors and innovative discoveries and development opportunities. The message is clear – long life is here to stay. And for the cryptocurrency industry or a world full of trend-setting and tech-savvy people, now is the time to start gaining momentum in this amazing space.
Lifetime Service Agreements
Shrouded in obscure rhetoric in the media, the Altos Labs convention is indicative of a high level of interest in the diverse lifestyle sector. The deal, which was awarded $3 billion on its first day, is considered the largest biotech deal to date to attract talent. The first management team consists of world-renowned researchers, policymakers and clinicians who are committed to finding new frontiers in the science of anti-aging.
Altos ads remind us of Calico Labs, another long-standing company announced in 2013 by Google co-founder Larry Page. While the Google subsidiary has been the subject of performance questions, it has successfully published its first initial cell reprogramming release in May 2021. And it’s not just tech executives that are making headlines for investment: Agreements in the last two months alone include areas like Stem cell therapy, liver regeneration, targeted aging, reproductive life, and more.
Obviously, the best innovators on the planet want to live longer. It is in our power to make long-term technology available to everyone when it becomes available to the public.
Related Topics: Crypto leaders are obsessed with life extension. That’s why
Discoveries for many years
Insilico Medicine, a Hong Kong-based drug development company, announced a major breakthrough at the end of 2021. The first drug discovered by artificial intelligence has been tested on humans. The drug will be used to treat idiopathic pulmonary fibrosis, a chronic lung disease, and early preliminary studies have shown promising results. This is the first material discovered by artificial intelligence to reach this stage and is an exciting indicator of new inventions to come. Artificial intelligence is an important area of longevity research that has countless applications to drug discovery and beyond.
Other exciting new areas include cell regeneration, herbal supplements, and advances in portable technology that helps track aging-related diseases. Charities such as VitaDAO and the Longevity Science Foundation are working tirelessly to fund research into these early ideas and help them achieve public acceptance.
Related Topics: Next Generation Computed Health is Here
Development of a sector with a long service life
On Deck, a company that offers accelerator programs for top talent across sectors, launched its first Longevity Biotech Fellowship in June 2021. The first group boasts lifetime participation from top biotech companies including Turn.bio, Juvena Therapeutics, Retro Sciences, and more. . Researchers from universities such as Yale University, the University of Washington, and ETH Zurich have also contributed to the coordinated community. On Deck is currently accepting orders for its second set starting later this month. The society claims to be pushing the boundaries of traditional health, and the biotech ecosystem is growing one member at a time.
Longevity also reaches public consciousness through international organizations. Martha Davey, director of the Stanford Center for Longevity, contributed to a World Economic Forum article on the social implications of longevity.